

**STICHTING DUCHENNE DATA FOUNDATION
AT BERGEN OP ZOOM**

Annual Report 2022

October 17, 2024

CONTENTS

Pagina

AUDITOR'S REPORT

1	Engagement	2
2	Accountant's compilation report	2
3	Results	4
4	Financial position	5

MANAGEMENT BOARD REPORT

1	Management board report	7
---	-------------------------	---

FINANCIAL STATEMENTS

1	Balance sheet as at December 31, 2022	15
2	Statement of the financial activities over 2022	17
3	Notes to the financial statements	18
4	Notes to the balance sheet as of December 31, 2022	21
5	Notes to the statement of financial activities 2022	25

OTHER INFORMATION

1	Audit	28
2	Recognition of the loss for 2022	28

AUDITOR'S REPORT

To the management of
Stichting Duchenne Data Foundation
Warmoesdreef 10
4614 HC Bergen op Zoom

<i>Reference</i>	<i>Processed by</i>	<i>Date</i>
11201	HB-IL	October 17, 2024

Dear members of the Executive Board,

We hereby send you the report regarding the financial statements for the year 2022 of your company.

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2022 of your company, including the balance sheet with counts of € 391,270 and the statement of financial activities with a negative result of € 91,687.

2 ACCOUNTANT'S COMPILATION REPORT

To: the management

The financial statements of Stichting Duchenne Data Foundation at Bergen op Zoom have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at December 31, 2022 and the profit and loss account for the year 2022 with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, "Compilation engagements", which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with Part 9 of Book 2 of the Civil Code. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting Duchenne Data Foundation. We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the "Verordening Gedrags- en Beroepsregels Accountants" (VGBA). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

For further information on the nature and scope of a compilation engagement and the VGBA we refer you to www.nba.nl/uitleg-samenstellingsverklaring.

2.1 Recognition of the 2021 loss

The result amounting to € 5,417 has been carried forward as accumulated deficit.

3 RESULTS

3.1 Development of income and expenses

The results for 2022 amounts negatief € 91,687 to negatief € 5,417 for 2021. The results for both years can be summarized as follows:

	2022	2021
	€	€
Income		
Income from individuals	130,000	125,500
Subsidies	34,309	-
Other income	177,416	147,400
Gross margin	341,725	272,900
Expenditure		
Expenditure on activities	305,443	159,594
Depreciation of tangible fixed assets	36	-
Office expenses	82,296	80,145
Publicity expenses	-	252
General expenses	44,285	38,053
Sum of expenses	432,060	278,044
Resultaat	-90,335	-5,144
Financial income and expenses		
Interest and similar expenses	-1,352	-273
Result	-91,687	-5,417

4 FINANCIAL POSITION

The balance sheet can be summarized as follows:

	12/31/2022		12/31/2021	
	€	€	€	€
Long term funds:				
Reserves and funds		342,042		433,729
Long term investments:				
Tangible fixed assets		3,053		-
Working capital		<u>338,989</u>		<u>433,729</u>

This amount is applied as follows:

Receivables, prepayments and accrued income	108,148		90,138	
Cash and cash equivalents	<u>280,069</u>		<u>379,539</u>	
		388,217		469,677
Debit: Short-term debt		<u>49,228</u>		<u>35,948</u>
Working capital		<u>338,989</u>		<u>433,729</u>

Yours sincerely,
Stolwijk Registeraccountants & Belastingadviseurs B.V.

I.M. van Lexmond AA

MANAGEMENT BOARD REPORT

Activity Report

2022

Purpose of this document

The purpose of this Board Management Report is to present and summarize the activities performed by the Board and employees of the Duchenne Data Foundation (DDF) in 2022. This report will serve as a communication tool to update the current Board members on the work and activities performed and completed in the previous year.

Composition and roles of Board members

The board members are:

- Paliouras, G. (Chair and Director R&D) since 01/01/2020
- Schreur, R. (Director of Finance and Business Development) – since 06/12/2021
- Bayley, K. (Director of Community Empowerment) – From 25/05/2021 to 20/07/2022
- Ajaikumar, BS. (Director of Clinical Programs) – since 01/10/2021
- Arjen Bergsma (Director of Data Services) – since 01/01/2022

Mission and Vision

Motivation

DDF believes that patients should be able to own, control, and share their data. Therefore, DDF fosters multi-source data connection, so that people living with dystrophinopathies can live their lives to the fullest. By building the missing link between various sources of data, evidence is generated to optimize Research and Development, as well as care practices.

Our goal is to accelerate the pathway to the development of innovative therapies, improve care and best practices, reduce misinformation and promote participation in the global dystrophinopathy community.

Our mission is to connect the fragmented data in the field of dystrophinopathies and test innovative solutions, scaling them to make a global impact.

Our vision is to bring data to life to improve the world of dystrophinopathies.

Strategy

Strategic direction

The strategic direction of DDF is built around 4 key pillars:

1. Research & Development
2. Standards of Care & Quality of Life
3. Education & Capacity Building
4. Data Equity & Access

Research & Development

DDF connects data to generate new evidence for more efficient and faster research in therapy development and care. The aim is to create an environment of dystrophinopathy data from various sources and locations, following the strict standards of data governance and ['FAIR'](#) principles. This evidence will inform the development of best care practices and therapies and support and inform regulatory and policy processes. The organization will enable the safe exchange of data and information to inform all areas of research and stakeholders.

Standards of Care & Quality of Life

DDF strives for all people living with dystrophinopathies around the world to have access to the latest standards of care and the best quality of life. This includes early diagnosis and surveillance, alongside quality-of-life initiatives. This will be achieved by collecting and analyzing data related to patient needs and preferences and connecting patients with the services they need.

Education & Training

DDF provides training to all stakeholders. The goal is to empower the voice of the global dystrophinopathy community to ensure research is patient- and family-led and centered. DDF will work alongside the World Duchenne Organization to facilitate the exchange of timely, evidence-based, and accurate information so all stakeholders can make informed decisions. This includes, but is not limited to, training on clinical trials and research, and patients being in control of their data.

Data Governance & Access

People should be able to own, control, and share their data. DDF advocates for people living with dystrophinopathies to achieve this. At the same time, the dystrophinopathy community should be able to benefit from the insights of the data.

Activities performed in 2022

1. Administration and management activities

- Weekly meetings have been taking place between the Chair of the Board and the Project Manager, as well as the Technical Officer. The purpose of the meetings is to present the overview of the tasks, update on technological advancements regarding the DDF digital tools, address any challenges/issues related to the DDF projects and EU-funded projects, and plan next steps.
- Seven meetings took place with all staff and board members involved in DDF, including invitees from the WDO board. These meetings provided an opportunity to update everyone about progress being made in each of the DDF projects and get feedback and ideas.
- Seven separate meetings took place among the members of the DDF board. The purpose of such meetings was to discuss running issues and make appropriate decisions. Changes to the strategy of DDF were also decided in these meetings.

Evaluation: Overall, these interactions were instrumental in ensuring project success, and promoting a culture of transparency and teamwork.

2. Communication/dissemination activities

- In 2022, we worked on further improving the identity and image of DDF to communicate and disseminate better with our audience
- A poster for Duchenne Map was presented at the annual European Conference on Rare Diseases (ECRD). The poster was among the top scoring posters for this conference, and the abstract was published in the Orphanet Journal of Rare Diseases (OJRD).

Evaluation: Interest in the activities of DDF increased. The number of followers on social media, as well as subscribers in our Newsletter have also increased.

3. Projects

Internal DDF Projects

- [Duchenne Data Repository](#)

The Duchenne Data Repository (DDR) is a storage location that can host a range of data types, including pre-clinical, natural history, clinical trials, patient-generated health data, and others. DDR aims to facilitate the findability of dystrophinopathy data stored in different locations through the development of metadata catalogs. DDR promotes FAIR data principles and is compliant with all GDPR, security, data protection, and privacy standards and policies.

Outcomes: New functionalities based on BIND project partners needs/preferences were developed and integrated in the database stored in DDR. DDR is being used from the BIND consortium partners to store and exchange datasets. Discussions with external public repositories continued for future dystrophinopathy data connections. An advanced version of the architecture and functionalities of the DDR was designed in 2022.

Project Status: Ongoing

Evaluation: The visibility and use of DDR increased. An advanced version of the DDR was planned for 2023.

- [Duchenne Map](#)

Duchenne Map is an online platform connecting Duchenne/Becker Muscular Dystrophy (DMD/BMD) families with their local patient organizations, healthcare providers, care centers, researchers, research institutions, and pharmaceutical companies. Duchenne Map offers a secure and inclusive platform where all stakeholders share reliable information.

Project Status: The project was paused until funding will be secured to implement the tasks described in the project plan.

European Projects

- [BIND Project](#)

This EU-funded project connects 19 partners and aims to address learning and behavioral issues in DMD/BMD.

Outcomes: A dedicated database, stored in DDR, was developed, and serves as the central storage of the newly generated BIND datasets. New datasets of the project were received and stored.

Project Status: Ongoing

Evaluation: DDF in collaboration with the EBRAINS Research Infrastructure (in-kind contribution) and LUMC (project partner) is responsible for the organization of FAIR workshops and implementation of FAIR processes for the BIND datasets and metadata. Security, data protection and data privacy policies are in place for DDR and monitored continuously by the DDF Information Security Officer. Connection with the EBRAINS database is planned for 2023.

- [EURO-NMD Registry Hub](#)

The general objective of this EU-funded project is to build a unified Registry Hub for neuromuscular diseases, including undiagnosed patients, and connect with the existing registries.

Outcomes: DDF has actively participated in the Steering Committee and significantly contributed in the communication/dissemination activities of the project. DDF also participated in technical working group discussions, testing technical features of the Registry and contributing to FAIR workflows planned for interoperability with pilot registries during the lifetime of the project. DDF also contributed to the drafting of a publication for the EURO-NMD Registry.

Project Status: Ongoing

Evaluation: DDF's active involvement and contributions have greatly enriched the project's outcomes and fostered a spirit of collaboration that will benefit all stakeholders involved.

Projects in collaboration with the World Duchenne Organization

- **DMD Emergency Program**

The DMD Emergency Program aims to support local patient organizations and communities dealing with unexpected emergencies.

Outcomes: Supported the DMD/BMD families leaving Ukraine, due to war. Medical equipment was donated to families staying in the country with DMD/BMD children.

Project Status: Ongoing

Evaluation: New funding was received for future emergencies.

- **Stronger Together Project**

The Stronger Together Project aims to promote education within the global community.

Outcomes: The project includes the Duchenne Patient Academy (DPA), which has now been established as a major educational event of the community. In 2022, DPA took place online, bringing together over 70 attendees from 43 countries over the span of three days. The program consisted of 6 sessions, each co-developed by experts in their respective fields. Dedicated panel discussions were moderated by the key speaker, guided by the participants' questions and comments. In addition to DPA, the project supports many local and international events, focus groups, and multimedia content creation.

Project Status: Ongoing

Evaluation: Participation and feedback collected in the various events has been very positive and encouraging to continue.

- **Duchenne CAB**

The Duchenne CAB is an international board consisting of independent, autonomous, and trained patient representatives. The goal is to provide its collective knowledge and expertise to accelerate research, development, clinical trials, and access to effective treatments for DMD and BMD worldwide.

Outcomes: The 9th and 10th rounds of meetings with stakeholders of the wider community took place in 2022. The 9th round took place in May in a hybrid fashion (online and in-person), bringing together community representatives from 12 countries and five companies. The 10th round happened in October, it was also hybrid and brought together CAB members from 12 countries and four companies.

Project Status: Ongoing

Evaluation: The Duchenne CAB continues to offer meaningful support to companies to promote better treatment and patient-centered research.

Conclusions

In 2022, DDF participated and co-led several international projects to the benefit of the DMD community. These projects advanced successfully and addressed several aspects of interest to the dystrophinopathy community, including optimal sharing of research and clinical data, training of patient advocates, and creation of digital applications to facilitate discoverability of and accessibility to dystrophinopathy data. DDF is advancing and continuously enriching its activities to improve the world of dystrophinopathies.

ANNUAL ACCOUNTS 2022

1 BALANCE SHEET AS AT DECEMBER 31, 2022
(after result appropriation)

	December 31, 2022		December 31, 2021	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Tangible fixed assets (1)		3,053		-
CURRENT ASSETS				
Receivables, prepayments and accrued income (2)				
Account receivable	93,010		75,000	
Other receivables, deferred assets	15,138		15,138	
		108,148		90,138
Cash and cash equivalents (3)		280,069		379,539
		<u>391,270</u>		<u>469,677</u>

	December 31, 2022		December 31, 2021	
	€	€	€	€
EQUITY AND LIABILITIES				
RESERVES AND FUNDS (4)				
Unrestricted funds, designated	250,000		250,000	
Designated reserve projects - BIND	28,684		32,162	
Unrestricted funds, general	63,358		151,567	
		342,042		433,729
CURRENT LIABILITIES (5)				
Account payable	1,652		13,462	
Taxes and social securities	38,667		18,225	
Other liabilities and Accruals and deferred income	8,909		4,261	
		49,228		35,948
		<u>391,270</u>		<u>469,677</u>

2 STATEMENT OF THE FINANCIAL ACTIVITIES OVER 2022

	Balance 2022	Balance 2021
	€	€
Income		
Income from individuals	(6) 130,000	125,500
Subsidies	(7) 34,309	-
Other income	(8) 177,416	147,400
Sum of income	341,725	272,900
Expenses		
Expenditure on activities	305,443	159,594
Costs of support		
Amortisation and depreciation	36	-
Office expenses	(11) 82,296	80,145
Publicity expenses	(12) -	252
General expenses	(13) 44,285	38,053
	126,617	118,450
Balance before financial income and expense	-90,335	-5,144
Financial income and expenses	(14) -1,352	-273
Result	-91,687	-5,417
Appropriation of the results		
Designated reserve projects - BIND	-3,478	-16,658
Unrestricted funds, general	-88,209	11,241
	-91,687	-5,417

3 NOTES TO THE FINANCIAL STATEMENTS

GENERAL

Activities

The activities of Stichting Duchenne Data Foundation (CoC file 64601188), with registered offices in Bergen op Zoom, mainly consist of the following: The worldwide collaboration between Duchenne Parent Organizations in order to improve the understanding of the course of disease process, the effect of treatment methods, the needs and preferences and all other aspects of all those affected by Duchenne muscular dystrophy (DMD and BMD).

Registered office, legal form and registration number at the chamber of commerce

The registered and actual address of Stichting Duchenne Data Foundation is Warmoesdreef 10, 4614 HC, in Bergen op Zoom of business and is registered at the chamber of commerce under number 64601188.

Estimates

In applying the principles and policies for drawing up the financial statements, the directors of Stichting Duchenne Data Foundation make different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under Book 2, article 362, paragraph 1, the nature of these estimates and judgments, including related assumptions, is disclosed in the notes to the relevant financial statement item.

GENERAL ACCOUNTING PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with the guidelines for annual reporting for small organisations without profit strife (Rjk C1). These are in line with the requirements for small legal entities that fall under Title 9 Book 2 of the Dutch Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

General

Tangible fixed assets

De materiële vaste activa worden gewaardeerd op verkrijgingsprijs, verminderd met de cumulatieve afschrijvingen en indien van toepassing met bijzondere waardeverminderingen. De afschrijvingen worden gebaseerd op de geschatte economische levensduur en worden berekend op basis van een vast percentage van de verkrijgingsprijs, rekening houdend met een eventuele residuwaarde. Er wordt afgeschreven vanaf het moment van ingebruikneming. Op terreinen wordt niet afgeschreven.

Securities

Upon initial recognition the receivables on and loans to participations and other receivables are valued at fair value and then valued at amortised cost, which equals the face value, after deduction of any provisions. The fair value and amortised cost equal the face value. Any provisions for the risk of doubtful debts are deducted. These provisions are determined based on individual assessment of the receivables.

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

Reserves en fondsen

Unrestricted funds, designated

The Unrestricted funds, designated are reserves with a more limited spending option, whereby the limitation is made by the board. The nature of the limitation is explained later.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

ACCOUNTING PRINCIPLES FOR THE DETERMINATION OF THE RESULT

Determination of the result

The result is determined based upon the difference between the nett income and the costs and other expenses taking into account the aforementioned valuation principles.

Income from individuals

Income from private individuals an private companies are general donations for the foundation

Subsidies

Operating subsidies are recorded as income in the profit and loss account in the year in which the subsidised costs were incurred or income was lost or when there was a subsidised operating deficit. Income is recognised when it is probable that it will be received.

Subsidies related to investments in tangible fixed assets are deducted from the asset to which they relate and recorded in the profit and loss account as part of the amortisation costs.

Expenditure on activities

The expenditure on activities consists of the cost directly related to the activities.

Gross margin

The gross operating profit and loss comprises net turnover, the changes in inventories of finished goods and work in progress, work performed by the entity and capitalised, other operating income, cost price and cost of outsourced work and other external charges.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.

Employee expenses

The benefits payable to personnel are recorded in the profit and loss account on the basis of the employment conditions.

The personnel costs are fully allocated to Patient Academy.

Financial income and expenses

Interest income and interest expenses

Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2022

ASSETS

	<u>12/31/2022</u>	<u>12/31/2021</u>
	€	€
1. Tangible fixed assets		
Office inventory	3,053	-

	<u>Office inventory</u>
	€
<i>Carrying amount as of January 1, 2022</i>	
Purchase price	-
Cumulative depreciation and impairment	-
	<u>-</u>

<i>Movement</i>	
Investments	3,089
Depreciation	-36
	<u>3,053</u>

<i>Carrying amount as of December 31, 2022</i>	
Purchase price	3,089
Cumulative depreciation and impairment	-36
	<u>3,053</u>

<i>Depreciation rates</i>	
Office inventory	20

2. Receivables, prepayments and accrued income

	<u>12/31/2022</u>	<u>12/31/2021</u>
	€	€
<i>Account receivable</i>		
Account receivable	93,010	76,000
Provision for accounts receivable	-	-1,000
	<u>93,010</u>	<u>75,000</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	<u>12/31/2022</u>	<u>12/31/2021</u>
	€	€
<i>Other receivables and prepayments</i>		
Current account WDO	14,176	14,176
Insurance	<u>962</u>	<u>962</u>
	<u>15,138</u>	<u>15,138</u>

3. Cash and cash equivalents

NL75ABNA0620549920	<u>280,069</u>	<u>379,539</u>
--------------------	----------------	----------------

The liquid resources are valued at nominal value. The liquid resources available as at December 31, 2022 are freely available to the Stichting Duchenne Data Foundation.

EQUITY AND LIABILITIES

	<u>12/31/2022</u>	<u>12/31/2021</u>
	€	€
4. Reserves and funds		
Unrestricted funds, designated	250,000	250,000
Designated reserve projects - BIND	28,684	32,162
Unrestricted funds, general	63,358	151,567
	<u>342,042</u>	<u>433,729</u>
Unrestricted funds, designated		
Selfinitiated Projects	100,000	100,000
Continuity reserves	150,000	150,000
	<u>250,000</u>	<u>250,000</u>
	<u>2022</u>	<u>2021</u>
	€	€
<i>Selfinitiated Projects</i>		
Carrying amount as of January 1	100,000	100,000
Carrying amount as of December 31	<u>100,000</u>	<u>100,000</u>
<i>Continuity reserves</i>		
Carrying amount as of January 1	150,000	150,000
Carrying amount as of December 31	<u>150,000</u>	<u>150,000</u>
<i>Designated reserve projects - BIND</i>		
Carrying amount as of January 1	32,162	48,820
Result allocation	-3,478	-16,658
Carrying amount as of December 31	<u>28,684</u>	<u>32,162</u>
<i>Unrestricted funds, general</i>		
Carrying amount as of January 1	151,567	140,326
Allocation of financial year net result	-88,209	11,241
Carrying amount as of December 31	<u>63,358</u>	<u>151,567</u>

5. Current liabilities

	<u>12/31/2022</u>	<u>12/31/2021</u>
	€	€
<i>Account payable</i>		
Account payable	1,652	13,462
	<u>1,652</u>	<u>13,462</u>
<i>Taxes and social securities</i>		
VAT	38,048	17,642
Pay-roll tax	619	583
	<u>38,667</u>	<u>18,225</u>
<i>VAT</i>		
VAT last period 2022	20,406	-
VAT supplementation 2021	11,865	11,865
VAT supplementation 2020	5,777	5,777
	<u>38,048</u>	<u>17,642</u>
<i>Pay-roll tax</i>		
Pay-roll tax	619	583
	<u>619</u>	<u>583</u>
<i>Other liabilities and Accruals and deferred income</i>		
Audit costs	8,909	3,000
Invoices to receive	-	1,261
	<u>8,909</u>	<u>4,261</u>

5 NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES 2022

	Balance 2022	Balance 2021
	€	€
6. Income from individuals		
Donations	130,000	125,500
7. Subsidies		
European Commission subsidy BIND	34,309	-
8. Other income		
Income Community Advisory Board	177,416	97,400
Income Emergency Programm	-	50,000
	<u>177,416</u>	<u>147,400</u>
9. Expenditure on activities		
Costs of congress and seminars	2,047	85
Costs of Community Advisory Board	63,949	30,007
Costs of MAP	10,428	7,997
Costs of Patient Academy	36,649	30,435
Costs of Psycho Project	6,275	11,709
Costs of EURO NMD	3,960	1,168
Costs of Digital D&B Program	18,523	10,411
Costs of DDF Repository	35,054	10,739
Cost of BIND	37,787	16,658
Costs of FAIR	212	19,532
Costs of WDAD	12,000	853
Costs of Emergency Programm	20,182	20,000
Costs of Communicaction	58,377	-
	<u>305,443</u>	<u>159,594</u>
10. Employee expenses		
Wages and salaries	13,862	13,201
Social security charges	2,336	2,340
Other personnel costs	-16,198	-15,541
	<u>-</u>	<u>-</u>
<i>Wages and salaries</i>		
Gross wages	12,835	12,223
Gross holidaypay	1,027	978
	<u>13,862</u>	<u>13,201</u>
<i>Social security charges</i>		
Other social charges	<u>2,336</u>	<u>2,340</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	Balance 2022	Balance 2021
	€	€
<i>Other personnel costs</i>		
Travelling expenses	894	894
Allocated labour costs Patient Academy	-17,092	-16,435
	<u>-16,198</u>	<u>-15,541</u>
Staff		
During 2022 1 employee was employed on a full-time basis.(2020: 1)		
Amortisation and depreciation		
<i>Depreciation of tangible fixed assets</i>		
Office inventory	36	-
	<u>36</u>	<u>-</u>
Other operating expenses		
11. Office expenses		
Automation costs	82,296	79,970
Contributions and subscriptions	-	175
	<u>82,296</u>	<u>80,145</u>
12. Publicity expenses		
Publicity and advertisement	-	252
	<u>-</u>	<u>252</u>
13. General expenses		
Audit costs	8,130	8,100
Auditcosts previous years	3,409	3,401
consultancy fees	450	-
Insurance costs	1,011	1,011
Bank costs	574	432
Amortisation of doubtful debtors	-	1,000
Non-deductible VAT	30,739	23,566
Other general expenses	-28	543
	<u>44,285</u>	<u>38,053</u>
14. Financial income and expenses		
Interest and similar expenses	-1,352	-273
	<u>-1,352</u>	<u>-273</u>
<i>Interest and similar expenses</i>		
Other interest payable	-1,352	-273
	<u>-1,352</u>	<u>-273</u>

OTHER INFORMATION

OTHER INFORMATION

1 Audit

your company has utilized the exemption from an audit by virtue of art. 2:396, paragraph 7 of the Dutch Civil Code.

2 Recognition of the loss for 2022

The board of directors proposes to add the 2022 result to the other reserves for an amount of € 91,687. The General Meeting of Shareholders will be asked to approve the appropriation of the 2022 result, this proposition is already recognised in the financial statements.